Mingcheng Qian

Dr. Mingcheng Qian


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MQMingcheng Qian
Mingcheng Qian
ZSZhengyang Sun
Zhengyang Sun
XCXin Chen
Xin Chen
SCSerge Van Calenbergh
Serge Van Calenbergh

19 December 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZZZefeng Zhao
Zefeng Zhao
SRSongsong Ruan
Songsong Ruan
XMXiaoming Ma
Xiaoming Ma
QFQian Feng
Qian Feng
ZXZhuosong Xie
Zhuosong Xie
XZXiaohui Zheng
Xiaohui Zheng
The voltage-gated potassium channel Kv1.5, which mediates the cardiac ultra-rapid delayed-rectifier (IKur) current in human cells, has a crucial role in atrial fibrillation. Therefore, the design of selective Kv1.5 modulators is essential for the treatment of pathophysiological conditions involving Kv1.5 activity. This review summarizes the progress of molecular structures and the functionality of different types of Kv1.5 modulators, with a focus on clinical cardiovascular drugs and a number of active natural products, through a summarization of 96 compounds currently widely used. Furthermore, we also discuss the contributions of Kv1.5 and the regulation of the structure-activity relationship (SAR) of synthetic Kv1.5 inhibitors in human pathophysiology. SAR analysis is regarded as a useful strategy in structural elucidation, as it relates to the characteristics that improve compounds targeting Kv1.5. Herein, we present previous studies regarding the structural, pharmacological, and SAR information of the Kv1.5 modulator, through which we can assist in identifying and designing potent and specific Kv1.5 inhibitors in the treatment of diseases involving Kv1.5 activity.

11 October 2024 in Tetrahedron
Verified
Journal Article
Closed access
ZMZhuangzhuang Mu
Zhuangzhuang Mu
HXHaochi Xie
Haochi Xie
SGShundong Gan
Shundong Gan
HLHujin Li
Hujin Li
YHYanan Hou
Yanan Hou
XCXin Chen
Xin Chen

22 July 2023 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YLYan Li
Yan Li
JSJingjing Sun
Jingjing Sun
XWXiao Wang
Xiao Wang
ZLZhijie Luo
Zhijie Luo
XSXuemei Shao
Xuemei Shao
XCXin Chen
Xin Chen

27 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
VFVíctor Fernández-Dueñas
Víctor Fernández-Dueñas
MQMingcheng Qian
Mingcheng Qian
JAJosep Argerich
Josep Argerich
CACarolina Amaral
Carolina Amaral
MRMartijn D.P. Risseeuw
Martijn D.P. Risseeuw
FRANCISCO CIRUELAFRANCISCO CIRUELA
FRANCISCO CIRUELA
In recent years, new drug discovery approaches based on novel pharmacological concepts have emerged. Allosteric modulators, for example, target receptors at sites other than the orthosteric binding sites and can modulate agonist-mediated activation. Interestingly, allosteric regulation may allow a fine-tuned regulation of unbalanced neurotransmitter’ systems, thus providing safe and effective treatments for a number of central nervous system diseases. The metabotropic glutamate type 5 receptor (mGlu5R) has been shown to possess a druggable allosteric binding domain. Accordingly, novel allosteric ligands are being explored in order to finely regulate glutamate neurotransmission, especially in the brain. However, before testing the activity of these new ligands in the clinic or even in animal disease models, it is common to characterize their ability to bind mGlu5Rs in vitro. Here, we have developed a new series of fluorescent ligands that, when used in a new NanoBRET-based binding assay, will facilitate screening for novel mGlu5R allosteric modulators.

25 December 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
XSXinyan Shen
Xinyan Shen
XSXuemei Shao
Xuemei Shao
BDBowei Dong
Bowei Dong
YGYuting Gu
Yuting Gu
JSJingjing Sun
Jingjing Sun
MQMingcheng Qian
Mingcheng Qian